SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Space Exploration Technologies Corp., doing business as SpaceX, operates as an aerospace manufacturer, launch service provider, and satellite communications company. It is building the integrated hardware and software infrastructure of the future across space, connectivity, and AI. The firm designs, manufactures, launches, and operates products and services built on cutting-edge technologies, including the rockets and spacecraft. The company was founded by Elon Reeve Musk in 2002 and is headquartered in Starbase, TX.

Space Exploration Technologies Corp. - Ordinary Shares - Class A

SpaceX

SpaceXs quarterly results topped expectations and marked its first profit since its IPO, with rapid growth in its AI-compute business and plans for heavy infrastructure spending driving attention. Many traders welcomed the growth and outlook, while others questioned the valuation, spending and share-unlock risk; discussion of a possible Tesla merger added speculation, but no deal is assured.

Super Micro Computer, Inc. engages in the distribution and manufacture of information technology solutions and other computer products. Its products include twin solutions, MP servers, GPU and coprocessor, MicroCloud, AMD solutions, power supplies, SuperServer, storage, motherboards, chassis, super workstations, accessories, SuperRack and server management products. The company was founded by Charles Liang, Yih-Shyan Liaw, Sara Liu, and Chiu-Chu Liu Liang in September 1993 and is headquartered in San Jose, CA.

Super Micro Computer Inc

Super Micros preliminary first-quarter update sharply raised its revenue and gross-margin outlook, citing stronger AI-platform demand, sparking a surge in shares. Traders largely welcomed the update as evidence of robust AI-server demand and anticipated short covering, while some questioned whether the gains would hold given the companys execution and credibility concerns.

Netflix, Inc. engages in providing entertainment services. It also offers activities for leisure time, entertainment video, video gaming, and other sources of entertainment. It operates through the United States and International geographic segments. The company was founded by Marc Randolph and Wilmot Reed Hastings on August 29, 1997 and is headquartered in Los Gatos, CA.

Netflix Inc.

Netflix Inc

Netflixs earnings beat was overshadowed by softer fourth-quarter guidance, slowing revenue growth and a reduced advertising outlook, prompting a sharp selloff. Traders are debating whether the drop reflects worsening growth prospects or an overreaction to the outlook, with some pointing to continued profitability as a reason to buy the dip.

Tesla, Inc. engages in the design, development, manufacture, and sale of electric vehicles and energy generation and storage systems. It operates through the Automotive and Energy Generation and Storage segments. The Automotive segment includes the design, development, manufacture, sale, and lease of electric vehicles as well as sales of automotive regulatory credits. The Energy Generation and Storage segment is involved in the design, manufacture, installation, sale, and lease of solar energy generation, energy storage products, and related services and sales of solar energy systems incentives. The company was founded by Jeffrey B. Straubel, Elon Reeve Musk, Martin Eberhard, and Marc Tarpenning on July 1, 2003 and is headquartered in Austin, TX.

Tesla Inc

Teslas rebound is drawing attention amid confirmed formation of special committees to explore a potential SpaceX merger, though Musk said a deal is uncertain and would require shareholder support. Traders are split between enthusiasm over possible synergies and skepticism about the terms and timing, while positioning around Teslas Q3 earnings adds volatility.

Bloom Energy Corp. engages in the manufacture and installation of a solid oxide fuel-cell based power generation platform. Its product, Bloom Energy Server, converts standard low-pressure natural gas or biogas into electricity through an electrochemical process without combustion. The company was founded by K. R. Sridhar, John Finn, Jim McElroy, Matthias Gottmann, and Dien Nguyen on January 18, 2001, and is headquartered in San Jose, CA.

Bloom Energy Corp - Ordinary Shares - Class A

Q3 earnings expectations dominate, with traders debating whether results and guidance can support Bloom Energys premium valuation after a sharp pullback. Bulls point to fuel-cell demand from AI data centers, while skeptics cite valuation risk and broader weakness in AI-related stocks.

SK hynix, Inc. engages in the design, manufacture, and sale of semiconductor products. Its products include dynamic random access memory, not-AND flash memory, and multi-chip package. The company was founded on October 15, 1949 and is headquartered in Icheon, South Korea.

SK Hynix Inc - ADR

SK Hynix is being swept up in a sharp memory-chip and Korean-market selloff, with traders citing KOSPI weakness, foreign selling, and fears about Chinese competition and the durability of the AI-driven memory cycle. Bulls argue the decline is excessive given strong memory demand and low valuations, while bears see further downside risk from cyclical and oversupply concerns.

Myriad Genetics, Inc. is a molecular diagnostics and precision medicine company committed to advancing health and well-being for all. It develops and commercializes molecular tests that help patients and providers uncover genetic insights. The company was founded by Walter A. Gilbert, Mark H. Skolnick, and Peter D. Meldrum in May 1991 and is headquartered in Salt Lake City, UT.

Myriad Genetics, Inc.

Myriads sharp rally is driven mainly by its agreement to sell its prenatal testing business to Labcorp for $210 million in cash plus inventory value, which traders view as a major cash infusion and a shift toward oncology. Bulls see the deal as a balance-sheet and strategic positive, while skeptics argue that selling a revenue-generating unit leaves a smaller business with ongoing debt and execution concerns.

CorMedix, Inc. is a pharmaceutical and medical device company, which engages in the development and commercialization of therapeutic products for the prevention and treatment of diseases and conditions. The company was founded by Antony E. Pfaffle on July 28, 2006 and is headquartered in Berkeley Heights, NJ.

CorMedix Inc

The FDA accepted CorMedixs REZZAYO filing for priority review for prevention of invasive fungal disease, with a target decision in Q1 2027; traders see the potential label expansion as a major growth opportunity but note that approval is not assured. The community is divided between optimism about the expanded use and frustration that the news has had little effect on the share price, alongside continuing concerns about DefenCaths reimbursement and adoption.

Braze, Inc. operates a customer relationship management platform for mobile applications. Its application combines messaging, audience segmentation, analytics and user support in a single integrated solution. The firm offers push notifications, email, in-app messages, and news feed services. The company was founded by Mark Ghermezian, William Magnuson, and Jonathan Hyman on March 28, 2011 and is headquartered in New York, NY.

Braze Inc - Ordinary Shares - Class A

Braze Inc

Salesforces all-cash agreement to acquire Braze at a substantial premium drove the sharp share-price jump. Traders celebrated the buyout while debating the remaining merger-arbitrage spread and lengthy closing process, with some also weighing analyst downgrades and concerns about the deal valuation.

Rapport Therapeutics, Inc. engages in the discovery and development of transformational small molecule medicines for patients suffering from central nervous system disorders. It develops the RAP (receptor associated proteins) technology platform. The company was founded by Steven M. Paul and David Bredt in February 2022 and is headquartered in Boston, MA.

Rapport Therapeutics Inc.

Rapport Therapeutics Inc

Rapports RAP-219 Phase 2 trial in acute bipolar mania met its primary and secondary endpoints, prompting a burst of bullish interest. Traders are divided over whether the efficacy is strong enough to outweigh concerns about agitation and higher treatment discontinuations, with the initial rally fading amid profit-taking and short-selling.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

AnaptysBio, Inc. (ANAB) Reports Q2 Loss, Tops Revenue Estimates

AnaptysBio (ANAB) delivered earnings and revenue surprises of +76.09% and +3.03%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Alphyn Capital on Its Special-Situation Investment: AnaptysBio (ANAB)

Alphyn Capital on Its Special-Situation Investment: AnaptysBio (ANAB...

GSK's sBLA for Jemperli Gets FDA Priority Tag in Rectal Cancer

GSK's Jemperli gets FDA priority review for dMMR/MSI-H rectal cancer with a decision due in February 2027, while Hibsago wins Japan approval in CHB.

CorMedix (CRMD) Q2 Earnings and Revenues Top Estimates

CorMedix (CRMD) delivered earnings and revenue surprises of +11.54% and +7.64%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

GSK's Jemperli Delivers Promising Interim Data in Rectal Cancer

GSK reports positive interim phase II AZUR-1 data as Jemperli meets the primary endpoint in rectal cancer, supporting potential regulatory filings.

Is AnaptysBio (ANAB) Outperforming Other Medical Stocks This Year?

Here is how AnaptysBio, Inc. (ANAB) and Electromed, Inc. (ELMD) have performed compared to their sector so far this year.

Wall Street Analysts See a 38.75% Upside in AnaptysBio (ANAB): Can the Stock Really Move This High?

The consensus price target hints at a 38.8% upside potential for AnaptysBio (ANAB). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

AnaptysBio (ANAB) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now

After losing some value lately, a hammer chart pattern has been formed for AnaptysBio (ANAB), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.

RCKT Stock Down on Q1 Earnings Miss, Kresladi Launch in Focus

Rocket Pharmaceuticals shares fell after a wider-than-expected Q1 loss as the company focuses on the launch of newly approved gene therapy Kresladi.

Is AnaptysBio (ANAB) One of the Best Performing Healthcare Stocks so Far in 2026?

Is AnaptysBio (ANAB) One of the Best Performing Healthcare Stocks so Far in 2026...

AnaptysBio, Inc. is a clinical-stage biotechnology company, which engages in delivering innovative immunology therapeutics for autoimmune and inflammatory diseases. The firm’s product pipeline includes Rosnilimab, ANB033, ANB101, Jemperli, and Imsidolimab. It operates through the Biopharma and Royalty Management segments. The Biopharma segment focuses on the development and potential commercialization of innovative immunology therapeutics for autoimmune and inflammatory diseases. The Royalty Management segment manages the financial collaboration for Jemperli with GSK and for imsidolimab with Vanda. The company was founded by Andrew B. Cubitt, William J. Boyle, Kevin J. Kinsella, and Nicholas B. Lydon in November 2005 and is headquartered in San Diego, CA.

AnaptysBio Inc

ANAB Stock Falls After Company Sues GSK Unit Tesaro Again, Claims Fresh Breach Of 2014 Deal

Equity

Bullish Sentiment

<ul class="summary-bullets"><li>Anaptys alleges that Tesaro violated the terms of the 2014 deal between the two companies.&nbsp;</li><li>The company said that it approached Tesaro to resolve the claims, but Tesaro initiated a lawsuit against it.</li><li>A trial is now anticipated in July 2026, and milestone and royalty payments continue to be due to Anaptys during the proceedings.</li></ul><p>AnaptysBio, Inc. (ANAB) said on Friday that it has initiated litigation against GSK unit Tesaro, alleging a breach of the terms of the collaboration agreement between the two companies, inked in March 2014. This renewed battle adds to a fraught relationship between the two companies, with a trial now expected in July next year.</p><p><a href="https://stocktwits.com/symbol/ANAB">ANAB shares</a> dipped 10% in the pre-market session at the time of writing.</p><h2 class="st-heading-2">New Legal Fight</h2><p>Anaptys has<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://ir.anaptysbio.com/news-releases/news-release-details/anaptys-initiates-litigation-against-tesaro-gsk-subsidiary"> requested</a> that the court declare that Anaptys is entitled to all rights and remedies under the collaboration agreement. The company alleged that Tesaro violated exclusivity obligations by participating in past, ongoing, and upcoming governed clinical trials with PD-1 antagonists, a type of immunotherapy, and failed to use commercially reasonable efforts to obtain optimum commercial return for its immunotherapy called Jemperli. A trial is now anticipated in July 2026 and milestone and royalty payments continue to be due to Anaptys during the proceedings.</p><p>The company said that it approached Tesaro to resolve the claims, but Tesaro initiated a lawsuit against it. Tesaro, in turn, alleges that Anaptys breached the agreement between the two companies. Anaptys said that Tesaro’s claims are entirely without merit and that it intends to pursue all appropriate legal remedies against Tesaro.</p><h2 class="st-heading-2">Previous Litigation</h2><p>Anaptys filed a complaint previously against GSK in 2020, alleging that GSK’s planned trial of Zejula in combination with Merck’s Keytruda violated the exclusivity obligations under the 2014 deal.</p><p>The complaint resulted in a settlement that included a cash payment.</p><h2 class="st-heading-2">$100M Stock Repurchase Plan</h2><p>Separately, Anaptys also announced that its Board of Directors has authorized an amended stock repurchase plan under which the company may repurchase up to $100 million of the company’s outstanding common stock. This is in addition to the $6.4 million that remained as of Nov. 20, 2025, under the current $75 million stock repurchase plan.</p><p>The shares may be repurchased from time to time in open market transactions, and the stock repurchase plan will expire on March 31, 2026, the company said.</p><h2 class="st-heading-2">How Did Stocktwits Users React?</h2><p>On Stocktwits, retail sentiment around ANAB stayed within the ‘neutral’ territory over the past 24 hours while message volume stayed at ‘extremely low’ levels.</p><figure class="image"><img style="aspect-ratio:584/61;" src="data:image/png;base64,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" width="584" height="61" alt="ANAB’s Sentiment Meter and Message Volume as of 7:05 a.m. ET on Nov. 21, 2025 | Source: Stocktwits"><figcaption>ANAB’s Sentiment Meter and Message Volume as of 7:05 a.m. ET on Nov. 21, 2025 | Source: Stocktwits</figcaption></figure><p>ANAB stock has nearly tripled this year and gained 78% over the past 12 months.&nbsp;</p><p>Also See: <a href="https://stocktwits.com/news-articles/markets/equity/foxconn-to-pour-up-to-5b-into-us-plants-after-striking-servers-deal-with-openai/cLPMZruREOB">Foxconn To Pour Up To $5B Into US Plants After Striking Servers Deal With OpenAI</a></p><p><i>For updates and corrections, email newsroom[at]stocktwits[dot]com</i></p>

In this photo illustration an AnaptysBio logo is displayed on a smartphone screen in Athens, Greece on January 13, 2023. (Photo illustration by Nikolas Kokovlis/NurPhoto via Getty Images)

The dispute centers around Tesaro’s participation in PD-1 trials. 

Glaxosmithkline plc - ADR

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Fiscal Period	Estimated	Reported	Surprise	Result
Q3 '26	-$1.84	-$1.84	--	EXPECTED
Q2 '26	-$0.47	-$0.89	-92.09%	MISSED
Q1 '26	-$0.64	-$1.84	-185.91%	MISSED
Q4 '25	$0.86	$1.05	22.07%	BEAT
Q3 '25	-$1.21	$0.52	142.83%	BEAT

Feed

News

Sentiment

Earnings

Fundamentals

Info

ANAB Earnings

Upcoming Earnings: Q3 '26

Historical Earnings